JP2017521499A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521499A5
JP2017521499A5 JP2017523191A JP2017523191A JP2017521499A5 JP 2017521499 A5 JP2017521499 A5 JP 2017521499A5 JP 2017523191 A JP2017523191 A JP 2017523191A JP 2017523191 A JP2017523191 A JP 2017523191A JP 2017521499 A5 JP2017521499 A5 JP 2017521499A5
Authority
JP
Japan
Prior art keywords
conp
radiation
chemotherapeutic agent
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017523191A
Other languages
English (en)
Japanese (ja)
Other versions
JP6706255B2 (ja
JP2017521499A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040869 external-priority patent/WO2016011328A1/en
Publication of JP2017521499A publication Critical patent/JP2017521499A/ja
Publication of JP2017521499A5 publication Critical patent/JP2017521499A5/ja
Application granted granted Critical
Publication of JP6706255B2 publication Critical patent/JP6706255B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017523191A 2014-07-17 2015-07-17 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 Expired - Fee Related JP6706255B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025861P 2014-07-17 2014-07-17
US62/025,861 2014-07-17
PCT/US2015/040869 WO2016011328A1 (en) 2014-07-17 2015-07-17 Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020086617A Division JP2020158507A (ja) 2014-07-17 2020-05-18 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療

Publications (3)

Publication Number Publication Date
JP2017521499A JP2017521499A (ja) 2017-08-03
JP2017521499A5 true JP2017521499A5 (https=) 2018-08-23
JP6706255B2 JP6706255B2 (ja) 2020-06-03

Family

ID=55079076

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017523191A Expired - Fee Related JP6706255B2 (ja) 2014-07-17 2015-07-17 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
JP2020086617A Pending JP2020158507A (ja) 2014-07-17 2020-05-18 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020086617A Pending JP2020158507A (ja) 2014-07-17 2020-05-18 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療

Country Status (9)

Country Link
EP (2) EP3169312B1 (https=)
JP (2) JP6706255B2 (https=)
CN (2) CN106604719B (https=)
AU (1) AU2015289504B2 (https=)
BR (1) BR112017000800A8 (https=)
CA (1) CA2955384C (https=)
MX (1) MX387363B (https=)
RU (2) RU2704811C2 (https=)
WO (1) WO2016011328A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512761B2 (en) 2009-12-02 2019-12-24 Renovorx, Inc. Methods for delivery of therapeutic materials to treat pancreatic cancer
WO2014197362A1 (en) 2013-06-03 2014-12-11 Ramtin Agah Devices, methods and kits for delivery of therapeutic materials to a pancreas
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
WO2017174437A1 (en) * 2016-04-05 2017-10-12 Hospital Clínic De Barcelona Ceria nanoparticles for use in the treatment of hepatocellular carcinoma
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN111093373A (zh) * 2017-04-12 2020-05-01 V·J·班格万丁 组合物、包装的药物和使用泊沙康唑用于敏化抗性肿瘤的方法
CA3060407A1 (en) * 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
US11052224B2 (en) 2017-05-18 2021-07-06 Renovorx, Inc. Methods for treating cancerous tumors
US10695543B2 (en) 2017-05-18 2020-06-30 Renovorx, Inc. Methods for treating cancerous tumors
US12290564B2 (en) 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
KR102102535B1 (ko) * 2018-07-26 2020-04-21 서울대학교산학협력단 방사선 보호 나노입자
MX2021003710A (es) * 2018-09-28 2021-08-19 Univ Colorado Regents Metodos para prevenir y tratar inflamacion y fibrosis pulmonar.
RU2699670C1 (ru) * 2018-11-16 2019-09-09 Объединенный Институт Ядерных Исследований (Оияи) Способ повышения частоты образования двунитевых разрывов днк в клетках человека при действии ионизирующих излучений в условиях влияния радиомодификаторов
CA3181177A1 (en) * 2020-04-30 2021-10-04 University Of Central Florida Research Foundation, Inc. Dispensable nanoparticle based composition for disinfection
JP2024531479A (ja) 2021-08-27 2024-08-29 アセンタウィッツ ファーマシューティカルズ リミテッド 凍結乾燥製剤溶液および凍結乾燥製剤、ならびにそれらの方法および使用
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
US20250295677A1 (en) 2022-04-15 2025-09-25 Ascentawits Pharmaceuticals, Ltd. Method for treating cancer by using th-302 alone or in combination with parp inhibitor
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
WO2024061346A1 (zh) 2022-09-22 2024-03-28 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
TW202434258A (zh) 2023-02-27 2024-09-01 大陸商深圳艾欣達偉醫藥科技有限公司 溶液、凍乾製劑、凍乾製劑單位包裝、注射液及注射液配製方法
AU2024317010A1 (en) 2023-07-28 2026-02-26 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099798A (en) 1997-10-31 2000-08-08 Nanogram Corp. Ultraviolet light block and photocatalytic materials
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP1904072A4 (en) * 2005-06-27 2009-06-17 Edward Via Virginia College Of ANTI-INFLAMMATORY, RADIOPROTECTIVE CERTIFICATE OXIDE NANOPARTICLE CAPACITIES AND ENHANCING LONGEVITY
WO2009086416A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
WO2009132277A1 (en) * 2008-04-25 2009-10-29 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US9393439B2 (en) * 2010-03-01 2016-07-19 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
EP2841055A4 (en) * 2012-04-04 2015-09-16 Univ Duke METHOD OF USE OF CERIUM OXIDE NANOPARTICLES TO REDUCE OR PROTECT FROM RADIATION DAMAGE
DK2861212T3 (en) * 2012-06-13 2017-03-06 Cerion Llc Cerium oxide nanoparticles for the treatment of oxidative stress
EP2928877B1 (en) * 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
US10463734B2 (en) * 2014-04-25 2019-11-05 The Regents Of The University Of Michigan Nanoparticle therapy in cancer
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
GB201506381D0 (en) * 2015-04-15 2015-05-27 Isis Innovation Embolization particle

Similar Documents

Publication Publication Date Title
JP2017521499A5 (https=)
RU2019133284A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
JP2022009090A5 (https=)
JP2022022264A5 (https=)
NZ604029A (en) Methods of treating bladder cancer
JP5543956B2 (ja) 癌の処置のための方法および組成物
JP2014515373A5 (https=)
JP2013522303A5 (https=)
CA2531862A1 (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
JP2014516942A5 (https=)
RU2017119230A (ru) Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом
JP2018526460A5 (https=)
JP2013518124A5 (https=)
WO2015032011A1 (zh) 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途
JP2019508476A5 (https=)
JP2021169534A5 (https=)
Tu et al. Localized delivery of nanomedicine and antibodies for combating COVID-19
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2012525358A5 (https=)
EP2832356B1 (en) Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer
JP2016505050A5 (https=)
JP2011500589A5 (https=)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.